Two major studies released this week link treatments already on pharmacy shelves — a shingles vaccine and hormone replacement therapy — to significantly lower dementia risk, raising an uncomfortable question for the medical-industrial complex: if existing treatments can cut Alzheimer's risk by up to a quarter, why isn't confirming that finding a top research priority?

Over 6 million Americans suffer from Alzheimer's and related dementias, costing families and the system more than $300 billion annually. A 24% risk reduction from an available treatment should be urgent national news. Instead, expect the familiar pattern: cautious hedging, no rush to prove causation, and billions continuing to flow toward patentable new drugs that have largely failed to deliver.

A Brown University study published in the Annals of Internal Medicine examined records from more than 509,000 adults 66 and older in skilled nursing facilities. Those who received at least one dose of the recombinant shingles vaccine, Shingrix, showed a 24% relative reduction in dementia risk over four years compared to the unvaccinated.

"This is maybe the third or fourth study, and they all came to the same conclusion," Dr. Ajeet Sodhi, a clinical neurologist not involved in the research, told Fox News. "It seems that by giving patients the shingles vaccine called Shingrix, in the next couple of years, we see a clinically significant decline in the development of dementia."

A separate study out of the University of East Anglia and University of Exeter, examining more than 183,000 post-menopausal women in the UK Biobank, found HRT linked to a 10% lower overall dementia risk and a 16% reduction in Alzheimer's specifically. Women who started HRT between ages 51 and 56 saw a 23% reduced risk. Those who underwent surgical menopause and took HRT had a 26% lower dementia risk.

"Rather than asking simply whether HRT affects dementia risk, we've been able to identify which women are most likely to benefit, and when," said Professor David Llewellyn of the University of Exeter, as reported by The Independent.

Both studies show association, not proven causation — and the researchers acknowledge that. But follow the money. Pharmaceutical companies have poured billions into developing patentable Alzheimer's drugs, nearly all of which have failed or shown marginal benefit. Aduhelm, the controversial FDA-approved Alzheimer's drug, costs over $26,000 annually and showed such questionable efficacy that Medicare restricted coverage. When existing, finite-course treatments show stronger associations with risk reduction than billion-dollar drug pipelines, the funding priorities deserve scrutiny.

Fox News covered the shingles vaccine findings directly. The Independent focused on the HRT study. Neither connected the dots: the medical-industrial complex has little financial incentive to rigorously test whether existing treatments prevent dementia. A vaccine taken in two doses or a generic hormone therapy doesn't generate the recurring revenue of a daily patented pill taken for years.

The varicella-zoster virus that causes shingles lies dormant near the brain and spinal cord after chickenpox and can reactivate decades later. Researchers propose the vaccine may prevent vascular complications from the virus, including stroke, which contributes to vascular dementia. Sodhi noted a separate study published the same week showed Shingrix linked to clinically significant reductions in heart attacks and strokes as well.

"It's not at this time considered a treatment," Sodhi cautioned. "This association is very, very suggestive, but we can't say one-to-one it proves that this treats dementia."

Fair — correlation isn't causation. But when is the last time the National Institutes of Health prioritized a large-scale trial to answer that question for an existing treatment with no new patent upside? The incentive structure runs the other direction. New patents fund the research, the journals, the conferences, and the careers.

The question isn't whether these treatments prevent dementia — that remains unproven. The question is why the establishment seems content to leave it unproven while American families wait for answers.